5 active not recruiting, 3 completed, 3 recruiting, 1 suspended. 9 Phase 2, 5 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 3, Recruiting 3, Active not recruiting 2, Unknown 1 |
| Phase 1 | 5 | Active not recruiting 2, Completed 1, Suspended 1, Terminated 1 |
| Phase 3 | 2 | Active not recruiting 2 |
Follow Sarcomatoid Renal Cell Carcinoma: new trials by email Literature Review of Sarcomatoid Renal Cell Carcinoma trials Research Report on Sarcomatoid Renal Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery Biospecimen Collection, Clostridium butyricum CBM588 Strain, Computed Tomography - Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 62 | 2026-07-08 | 2026-10-19 |
| An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 91 | 2024-08-06 | 2026-06-15 |
| A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma AK104, Axitinib - Renal Cell Carcinoma, First-line Treatment | Phase 1 / Phase 2 | Active not recruiting | Hao Zeng | 37 | 2023-11-17 | 2026-04-07 |
| Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma | Phase 1 | Suspended | City of Hope Medical Center | 31 | 2023-10-06 | 2026-10-08 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors INCB099318 - Advanced Solid Tumors, MSI-H/dMMR Tumors | Phase 1 | Terminated | Incyte Corporation | 105 | 2021-03-26 | 2025-10-16 |
| Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study Biospecimen Collection, Bone Scan, Cabozantinib - Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1175 | 2019-06-07 | 2026-10-26 |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 314 | 2019-05-13 | 2026-10-27 |
| ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) Cabozantinib - Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1 | Phase 2 | Completed | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 35 | 2019-04-11 | 2025-08-08 |
| Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma Cabozantinib, Sunitinib Malate - Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 32 | 2018-05-15 | 2026-07-16 |
| Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) Nivolumab, Ipilimumab - Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1 | Phase 2 | Unknown | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 85 | 2017-10-19 | 2022-02-16 |
| Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy Nephrectomy, Nivolumab, Patient Observation - Metastatic Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 819 | 2017-04-28 | 2026-08-28 |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 152 | 2015-07-22 | 2026-10-15 |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Pazopanib Hydrochloride - Carcinoma of the Collecting Ducts of Bellini, Chromophobe Renal Cell Carcinoma | Phase 2 | Completed | Mayo Clinic | 38 | 2013-05-16 | 2025-03-03 |
| Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer Bevacizumab, Sorafenib Tosylate, Pharmacological Study - Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 73 | 2005-05-01 | 2015-01-15 |
Carcinoma, Renal Cell (14) · Carcinoma, Transitional Cell (2) · Penile Neoplasms (2) · Urethral Neoplasms (2) · Urinary Bladder Neoplasms (2) · Urogenital Neoplasms (2) · Anus Neoplasms (1) · Carcinoma, Basal Cell (1) · Carcinoma, Merkel Cell (1) · Endometrial Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Lymphatic Metastasis (1) · Mesothelioma (1) · Nasopharyngeal Carcinoma (1) · Neoplasm Metastasis (1)
Adenocarcinoma (14) · Carcinoma (14) · Female Urogenital Diseases (14) · Female Urogenital Diseases and Pregnancy Complications (14) · Kidney Diseases (14) · Kidney Neoplasms (14) · Male Urogenital Diseases (14) · Neoplasms (14) · Neoplasms by Histologic Type (14) · Neoplasms by Site (14) · Neoplasms, Glandular and Epithelial (14) · Urogenital Diseases (14) · Urologic Diseases (14) · Urologic Neoplasms (13) · Urogenital Neoplasms (12)
Nivolumab (6) · Specimen Handling (6) · Ipilimumab (5) · Magnetic Resonance Spectroscopy (5) · cabozantinib (5) · CTLA-4 Antigen (4) · Axitinib (1) · Bevacizumab (1) · Biopsy (1) · Nephrectomy (1) · Observation (1) · Sorafenib (1) · Sunitinib (1) · Watchful Waiting (1) · pazopanib (1)
National Cancer Institute (NCI) (5) · Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2) · City of Hope Medical Center (2) · Hao Zeng (1) · Incyte Corporation (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1)
United States (11) · Australia (2) · Puerto Rico (2) · Belgium (1) · Canada (1) · China (1) · Denmark (1) · Finland (1) · Israel (1) · Norway (1) · Sweden (1) · United Kingdom (1)
Andrea B Apolo (2) · Brian Costello, M.D. (1) · Brian Shuch (1) · David Pook, MBBS FRACPMD (1) · Hao Zeng, Professor (1) · Jeffrey Sosman (1) · Lauren Harshman (1) · Louis Viviers, MD (1) · Matthew T Campbell (1) · Sumanta K Pal (1) · Tian Zhang (1) · Wesley Yip (1)
PMID 35031545, PMID 32915679, PMID 33526329, PMID 35304832, PMID 35383907, PMID 38942046, PMID 38954785, PMID 41693026, PMID 42580817
P30CA033572 (2), U10CA180821 (2), 2019 (1), P30CA068485 (1), U01CA099177 (1), U10CA180820 (1), UM1CA186712 (1), UM1CA186716 (1), UM1CA186717 (1), ZIABC011078 (1)